Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

Harvest Portfolios Group Inc. ("Harvest") announces the following distributions for Harvest High Income Shares ETFs for the month ending February 28, 2025. The distribution will be paid on or about ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. Ken Fisher is the founder and executive chairman of Fisher Asset Management ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In an era where financial literacy is increasingly recognized as a crucial ...

Mike Czapar-- Senior Vice President, Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor ...

Ethan Slater‘s ex-wife Lilly Jay has been doing her best to stay out of the public eye ever since their headline-making divorce in 2023 but we have learned some details about her life in the ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.